Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia
Status
Conditions
Treatments
Details and patient eligibility
About
Leucine-rich glioma inactivated 3(Lgi3) has been postulated to have a pro-inflammatory adipokine that inter-plays with other adipokines in adipogenesis and metabolic inflammation according to recent investigations. Thus, in this study, we sought to demonstrate that the treatment of statin can decrease Lgi3 level along with the decrease of the atherosclerosis to further evaluate the role of Lgi3 in atherosclerosis.
Full description
Patients who assigned to the pitavastatin treatment first group will be given the pitavastatin 4 mg qd treatment for 12 weeks after randomization, followed by wash-out period of 3 weeks and life-style modification treatment for 12 weeks. Similarly, patients who assigned to the life-style modification treatment first group, will be treated with life-style modification treatment for 12 weeks after randomization, followed by wash-out period of 3 weeks and pitavastatin treatment for 12 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 20-80 years
- Patients with intermediate or low cardiovascular risks needing the statin treatment
- Patients with intermediate or low cardiovascular risks treating the statin treatment
Exclusion criteria
- Patients without signed informed consent
- Patients with myopathy
- Pregnant women or women with potential childbearing
- Patients with diabetes
- Patients with established coronary artery disease
- Patients with heart failure
- Life expectancy less than 1 year
Trial design
Primary purpose
Allocation
Interventional model
Masking
50 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal